Adapting for the future: what can we learn from REMAP-CAP and COVID-19 pandemic trials?

This publication has 8 references indexed in Scilit:

• Tocilizumab, sarilumab and anakinra in critically ill patients with COVID-19: a randomised, controlled, open-label, adaptive platform trial
  Thorax, 2025
• The Rise of Adaptive Platform Trials in Critical Care
  American Journal of Respiratory and Critical Care Medicine, 2024
• Early treatment of COVID-19 with anakinra guided by soluble urokinase plasminogen receptor plasma levels: a double-blind, randomized controlled phase 3 trial
  Nature Medicine, 2021
• Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
  The Lancet, 2021
• Interleukin-6 Receptor Antagonists in Critically Ill Patients with Covid-19
  New England Journal of Medicine, 2021
• Dexamethasone in Hospitalized Patients with Covid-19
  New England Journal of Medicine, 2021
• Resist the Temptation of Response-Adaptive Randomization
  Clinical Infectious Diseases, 2020
• Remdesivir for the Treatment of Covid-19 — Final Report
  New England Journal of Medicine, 2020